Sector News

AbbVie, Genmab, with new data, prep FDA application for dual-acting cancer drug

April 16, 2022
Life sciences

Yescarta and Kymriah, known as CAR-T therapies, can help cancer patients by arming their immune cells to attack diseased tissue in types of lymphoma and leukemia. But, because the immune cells must be genetically engineered outside the body, treatment is lengthy, complicated and expensive.

The dual-acting, or “bispecific,” antibodies being developed by AbbVie and Genmab, Roche, and other companies like Johnson & Johnson and Regeneron, latch onto proteins on both diseased and immune cells to trigger an attack. Unlike CAR-T drugs, which are meant to be a one-time infusion, bispecific antibodies must be given regularly. In the case of this epcoritamab trial, patients received a subcutaneous shot every four weeks.

Data from 157 patients with large B cell lymphoma reported Wednesday showed that 63% responded to treatment with epcoritamab, although the company didn’t detail how many were driven into remission versus experiencing partial responses. In order to be included in the trial, patients had to have relapsed after at least two lines of therapy. Nearly 40% had previously received CAR-T treatment. READ MORE

by Jonathan Gardner

Source: biopharmadive.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.